GO:0004496 mevalonate kinase activity: Mechanism, Genes

Mevalonate kinase activity (GO:0004496) is a molecular function defined as the catalysis of the reaction: (R)-mevalonate + ATP = (R)-5-phosphomevalonate + ADP + 2 H+ [1, 4]. This enzymatic step is the first committed reaction of the mevalonate pathway, which produces isoprenoids, cholesterol, and other essential metabolites [1, 4]. In humans, the enzyme is encoded by the MVK gene, and its activity is critical for normal development and immune homeostasis [1, 4, 6]. Researchers study mevalonate kinase activity to understand metabolic control, autoinflammation, and the interface between metabolism and immunity [3, 5]. The clinical importance of mevalonate kinase activity is underscored by mevalonate kinase deficiency (MKD), a rare autosomal recessive autoinflammatory disorder caused by MVK mutations [1, 4, 6]. Patients present with recurrent fever, skin rash, and elevated inflammatory markers, and severe forms can include neurological involvement [1, 4]. The disease links a metabolic enzyme defect to dysregulated innate immune signaling, particularly interleukin-1β production. This connection has made mevalonate kinase a model for studying how metabolic pathways control inflammation [3, 5]. Beyond rare disease, mevalonate kinase activity influences trained immunity, a form of innate immune memory induced by metabolic and epigenetic reprogramming. The enzyme is also a potential target for anti-infective and immunomodulatory therapies, with structural studies of bacterial mevalonate kinases providing a foundation for inhibitor development. Thus, GO:0004496 is a focal point for research spanning enzymology, immunology, and translational medicine [1, 3, 4, 5, 8].

Mevalonate kinase activity (GO:0004496) is the catalytic function that transfers a phosphate group from ATP to (R)-mevalonate, yielding (R)-5-phosphomevalonate, ADP, and two protons [1, 4]. This reaction is the first committed and rate-limiting step in the mevalonate pathway, which supplies precursors for cholesterol, steroid hormones, dolichols, ubiquinone, and isoprenylated proteins [1, 4]. The activity is measured by monitoring the conversion of mevalonate to 5-phosphomevalonate, often using coupled enzymatic assays or radiolabeled substrates.

Mevalonate kinase activity is essential for the biosynthesis of isoprenoids and cholesterol, and its dysfunction causes mevalonate kinase deficiency, a rare autoinflammatory disease with significant morbidity [1, 4, 6]. The enzyme also plays a role in trained immunity, linking metabolism to epigenetic reprogramming and host defense. Understanding its catalytic mechanism and regulation provides insights into inflammatory diseases and potential therapeutic targets [5, 8].

The following genes and proteins are directly or indirectly involved in mevalonate kinase activity and its associated pathways.

Mevalonate kinase activity is regulated transcriptionally by SREBP-2, which senses sterol levels and controls expression of mevalonate pathway genes including MVK [1, 4]. Post-translationally, the enzyme can be inhibited by downstream metabolites such as geranylgeranyl pyrophosphate, providing feedback control [1, 4]. Inflammatory signaling can also influence pathway activity, as cytokines modulate enzyme expression and metabolite flux. Additionally, the mevalonate pathway integrates with cellular energy status through ATP availability, affecting kinase activity.

Mevalonate kinase deficiency is an autosomal recessive autoinflammatory disease caused by biallelic mutations in MVK, leading to reduced mevalonate kinase activity [1, 4, 6]. Clinical presentations range from hyper-IgD syndrome (HIDS) with recurrent fever and elevated IgD to severe mevalonic aciduria with neurological impairment [1, 4]. The disease is characterized by periodic fever, skin rash, arthralgia, and elevated acute-phase reactants [1, 4]. Diagnosis is supported by elevated urinary mevalonic acid and genetic testing [1, 4].

Reduced mevalonate kinase activity leads to increased caspase-1 activity and secretion of IL-1 family cytokines, including IL-1β and IL-18. This link between the metabolic defect and inflammasome activation explains the efficacy of IL-1 blockade in treating MKD. The mechanism may involve defective prenylation of small GTPases, which normally suppress inflammasome activity [1, 4, 5].

The mevalonate pathway, including mevalonate kinase, plays a role in trained immunity, where innate immune cells undergo metabolic and epigenetic reprogramming to mount enhanced responses upon secondary challenge. This has implications for vaccine design and host defense against infections. Dysregulation of this pathway may contribute to inflammatory diseases beyond MKD.

Mevalonate kinase is a potential target for anti-inflammatory therapies, and inhibitors of the mevalonate pathway are being explored for immunomodulation. In MKD, IL-1 inhibitors such as anakinra and canakinumab are used to control inflammation [1, 4]. Research into specific mevalonate kinase activators or downstream metabolite supplementation is ongoing [1, 4].

Mevalonate kinase activity can be measured using coupled enzymatic assays that monitor ADP production or NADH oxidation, or by radiometric assays with 14C-mevalonate. These methods are used to characterize wild-type and mutant enzymes, and to screen for inhibitors.

Metabolomic profiling by mass spectrometry quantifies mevalonate, 5-phosphomevalonate, and downstream isoprenoids in cells and body fluids [1, 4]. Stable isotope tracing can assess pathway flux and identify metabolic blocks [1, 4].

Genome-wide CRISPR knockout screens can identify genes that modify the effects of mevalonate kinase deficiency, including modifiers of inflammation and prenylation [1, 4, 5]. These screens help uncover synthetic lethal interactions and compensatory pathways [1, 4].

RNA sequencing and proteomics reveal changes in gene expression and protein abundance upon MVK manipulation, including inflammatory and metabolic pathways [3, 5]. These approaches identify biomarkers and therapeutic targets [3, 5].

Researchers studying mevalonate kinase activity-related genes often need to determine whether a candidate gene is causally involved in inflammatory or metabolic phenotypes. EDITGENE provides comprehensive CRISPR services to create precisely engineered cell models, enabling functional validation of MVK and related pathway genes.

Mevalonate kinase activity (GO:0004496) is a fundamental enzymatic function that controls the first committed step of the mevalonate pathway, with critical roles in cholesterol synthesis, prenylation, and immune regulation [1, 4]. Its dysfunction causes mevalonate kinase deficiency, a rare autoinflammatory disease, and contributes to broader inflammatory processes [1, 4, 5]. Continued research using advanced CRISPR models and multi-omics approaches will further elucidate its mechanisms and therapeutic potential [1, 3, 4, 5, 8].